Not available
Quote | Loxo Oncology Inc. (NASDAQ:LOXO)
Last: | $ |
---|---|
Change Percent: | 0.00% |
Open: | $N/A |
Close: | $234.66 |
High: | $N/A |
Low: | $N/A |
Volume: | 400 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Loxo Oncology Inc. (NASDAQ:LOXO)
Gain’s cutting-edge precision medicine platform and novel compounds enable therapeutic access to previously undruggable targets. Public investors can access this disruptive technology at a venture-like valuation. A clean balance sheet funds the business until H2 2023, with ...
Eli Lilly's (LLY) R&D group Loxo Oncology (LOXO) and Merus (MRUS) announce a research collaboration and exclusive license agreement that will leverage Merus' proprietary Biclonics platform along with the scientific and rational drug design expertise of Loxo Oncology (LOXO) at Lilly t...
Message Board Posts | Loxo Oncology Inc. (NASDAQ:LOXO)
Subject | By | Source | When |
---|---|---|---|
If I recall correctly, yes. | Zmill | investorshub | 07/13/2019 12:59:39 PM |
Zmill, did that in-depth research mention anything about | FooBarAndGrill | investorshub | 07/03/2019 9:46:43 PM |
in depth Research on LOXO https://wordpress.com/block-editor/post/msmoneymoves.c | Zmill | investorshub | 07/03/2019 2:36:21 PM |
Cancer drugs - drugs ALONE - $123 BILLION | 0whammies | investorshub | 01/07/2019 2:59:31 PM |
Congrats, LOXO up $91. in PM w/ merger! | crudeoil24 | investorshub | 01/07/2019 12:46:28 PM |
News, Short Squeeze, Breakout and More Instantly...
INDIANAPOLIS and STAMFORD, Conn. , Feb. 1, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) ("Lilly") and Loxo Oncology, Inc. (NASDAQ: LOXO) ("Loxo Oncology") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 197...